Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. O’Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 2016;128:233.

    Google Scholar 

  2. Mauro FR, Tedeschi A, Piciocchi A, Motta M, Iannella E, Farina L, et al. Outcome of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and/or 17p deletion/TP53 mutations treated with Ibrutinib according to a Named Patient Program (NPP) in Italy: preliminary analysis of a real life retrospective study. Blood 2016;128:2038.

    Google Scholar 

  3. Sharma RG, Call TG, Habermann TM, Ding W, Leis JF, Schwager S, et al. Outcomes of chronic lymphocytic leukemia patients with Richter syndrome. Blood 2013;122:4179.

    Article  Google Scholar 

  4. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood 2016;128:2199–205.

    Article  CAS  PubMed  Google Scholar 

  5. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: Results from a multi-center study of 683 patients. Annal Oncolo. 2017;28:1050–1056.

    CAS  Google Scholar 

  6. Jones J, Choi MY, Mato AR, Furman RR, Davids MS, Heffner LT, et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood 2016;128:637.

    Google Scholar 

  7. Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, et al. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. Eur J Haematol 2017;98:363–70.

    Article  PubMed  Google Scholar 

  8. Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:5094–100.

    Article  PubMed  Google Scholar 

  9. Dreger P, Schnaiter A, Rossi M, Paschka P, Bühler A, Zenz T, et al. SF3B1, NOTCH1 and TP53 mutations do not affect the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 6-year follow-up of the Gcllsg CLL3X trial. Blood 2012;120:966.

    Google Scholar 

  10. Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009;94:654–62.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747–53.

    Article  CAS  PubMed  Google Scholar 

  12. Moreno C, Villamor N, Esteve J, Colomer D, Bosch F, Campo E, et al. Clinical significance of minimal residual disease (MRD), as assessed by different techniques, after stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL). Blood 2005;106:2018.

    Article  Google Scholar 

  13. Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, et al. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2017;52:552–60.

    Article  CAS  PubMed  Google Scholar 

  14. van Gelder M, de Wreede LC, Bornhauser M, Niederwieser D, Karas M, Anderson NS, et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2017;52:372–80.

    Article  PubMed  Google Scholar 

  15. Michallet M, Sobh M, Milligan D, Morisset S, Niederwieser D, Koza V, et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 2010;24:1725–31.

    Article  CAS  PubMed  Google Scholar 

  16. Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, et al. Outcomes of cord blood transplantation using reduced-intensity conditioning for chronic lymphocytic leukemia: a study on behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire. Biol Blood Marrow Transplant 2015;21:1515–23.

    Article  PubMed  Google Scholar 

  17. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014;20:1573–9.

    Article  PubMed  Google Scholar 

  18. Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant 2015;50:S37–S9.

    Article  CAS  PubMed  Google Scholar 

  19. McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bolaños-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015;125:3024–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015;126:1033–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013;31:1310–6.

    Article  CAS  PubMed  Google Scholar 

  22. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009;113:4771–9.

    Article  CAS  PubMed  Google Scholar 

  23. Brammer JE, Khouri I, Gaballa S, Anderlini P, Tomuleasa C, Ahmed S, et al. Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning. Biol Blood Marrow Transplant 2016;22:493–8.

    Article  PubMed  Google Scholar 

  24. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–33.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013;48:S1–37.

    Article  PubMed  Google Scholar 

  26. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008;112:2990–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Walker I, Shehata N, Cantin G, Couture F, Dhedin N, Barty R, et al. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis 2004;33:222–6.

    Article  PubMed  Google Scholar 

  29. Schwarer AP, Bollard G, Kapuscinski M, Muirhead J, Diviney M, Hart C, et al. Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical haematopoietic SCT. Bone Marrow Transplant 2011;46:1331–8.

    Article  CAS  PubMed  Google Scholar 

  30. van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MCJ, Cornelissen JJ, Chamuleau ME, et al. Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplant 2016;51:799–806.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Gwendolyn van Gorkom.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Gorkom, G., van Gelder, M., Eikema, DJ. et al. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant 53, 255–263 (2018). https://doi.org/10.1038/s41409-017-0023-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-017-0023-2

Search

Quick links